[

dcgi

]
Representative Image
Representative Image

DCGI accepts proposal to study mixing of Covid-19 vaccine doses

By hindustantimes.com | Written by Karan Manral, New Delhi
PUBLISHED ON AUG 11, 2021 08:00 AM IST
The research will analyse mixing a dose each of Covaxin and Covishield. It will be conducted at Christian Medical College in Tamil Nadu's Vellore.
A Covid-19 vaccination centre in Kolkata (ANI/used only for representative purpose)
A Covid-19 vaccination centre in Kolkata (ANI/used only for representative purpose)

Zydus Cadila submits additional data on its Covid-19 vaccine to DCGI: Report

By hindustantimes.com | Written by Karan Manral
PUBLISHED ON JUL 27, 2021 08:33 PM IST
The Ahmedabad-based firm's vaccine candidate, ZyCoV-D, is expected to be approved in August.
A health worker holding up a vial of Covaxin, a Covid-19 vaccine at a school being used as a vaccination site in Kingsway Camp, Delhi (Sanchit Khanna / HT PHOTO),
A health worker holding up a vial of Covaxin, a Covid-19 vaccine at a school being used as a vaccination site in Kingsway Camp, Delhi (Sanchit Khanna / HT PHOTO),

Bharat Biotech submits Covaxin phase 3 trials data to DCGI: Reports

By hindustantimes.com | Written by Karan Manral | Edited by Amit Chaturvedi, New Delhi
PUBLISHED ON JUN 22, 2021 09:50 AM IST
Also, according to reports, the Subject Expert Committee (SEC) is likely to meet on Tuesday to review the phase 3 data.
The drug controller told the Delhi high court on Friday that Gautam Gambhir Foundation had committed an offence under Drugs and Cosmetics Act(Sonu Mehta/HT PHOTO)
The drug controller told the Delhi high court on Friday that Gautam Gambhir Foundation had committed an offence under Drugs and Cosmetics Act(Sonu Mehta/HT PHOTO)

Ready to face whatever the court decides: Gautam Gambhir on drug hoarding case

By hindustantimes.com, Hindustan Times, New Delhi
PUBLISHED ON JUN 04, 2021 08:55 PM IST
  • The Bharatiya Janata Party MP from East Delhi had been found guilty of unauthorisedly stocking and distributing Fabiflu pills to Covid-19 patients by the Delhi government's drug control department.
Vaccination centre at Dr. Babasaheb Ambedkar Hospital (Shatabdi Hospital) closed due vaccine shortage at Kandivali, in Mumbai. (Vijay Bate / HT Photo)
Vaccination centre at Dr. Babasaheb Ambedkar Hospital (Shatabdi Hospital) closed due vaccine shortage at Kandivali, in Mumbai. (Vijay Bate / HT Photo)

Serum seeks DCGI nod to manufacture Sputnik

By Rhythma Kaul, Hindustan Times. New Delhi
UPDATED ON JUN 04, 2021 04:36 AM IST
SII, applied to Indian regulator, the drugs controller general of India (DCGI), Dr VG Somani, on Wednesday to seek approval for grant of licence.
The cocktail of casirivimab and imdevimab has been developed by Swiss pharmaceutical giant Roche.(AFP File Photo)
The cocktail of casirivimab and imdevimab has been developed by Swiss pharmaceutical giant Roche.(AFP File Photo)

'A new weapon': Dr Naresh Trehan on Covid-19 antibody cocktail

By hindustantimes.com | Edited by Amit Chaturvedi, Hindustan Times, New Delhi
PUBLISHED ON MAY 26, 2021 05:12 PM IST
The cocktail of casirivimab and imdevimab came into limelight after it was administered to former US President Donald Trump when he tested positive for Covid-19 last year.
Responding to Prime Minister Narendra Modi’s call for preparedness against the pandemic, the DRDO took the initiative of developing anti-Covid therapeutic application of 2-DG(File photo)
Responding to Prime Minister Narendra Modi’s call for preparedness against the pandemic, the DRDO took the initiative of developing anti-Covid therapeutic application of 2-DG(File photo)

DCGI gives emergency approval of DRDO-developed anti-Covid oral drug

By Shishir Gupta, New Delhi
PUBLISHED ON MAY 08, 2021 01:42 PM IST
The oral drug has been developed by Institute of Nuclear Medicine and Allied Sciences, a lab of DRDO, in collaboration with Dr Reddy’s Laboratories, Hyderabad. Phase III clinical trial results have shown that this molecule helps in faster recovery of hospitalised patients and reduces supplemental oxygen dependence.
A man applies finishing touches to graffiti representing a vaccine, amidst the spread of coronavirus disease (Covid-19) in Kolkata, India, January 2, 2021.(REUTERS)
A man applies finishing touches to graffiti representing a vaccine, amidst the spread of coronavirus disease (Covid-19) in Kolkata, India, January 2, 2021.(REUTERS)

India’s vaccine jabs may start next week: Officials

Hindustan Times, New Delhi | By Rhythma Kaul
UPDATED ON JAN 05, 2021 07:01 AM IST
Prime Minister Narendra Modi said the world’s biggest inoculation drive against coronavirus is set to begin in the country, lauding scientists and technicians for the “Made in India” vaccines.
The permission document also states that the firm should ensure that “factsheet for the vaccine recipient or attendant is provided prior to administration of vaccine”.(REUTERS)
The permission document also states that the firm should ensure that “factsheet for the vaccine recipient or attendant is provided prior to administration of vaccine”.(REUTERS)

Second dose of Covishield vaccine should be administered between four to six weeks: DCGI

New Delhi | By Asian News International | Posted by Srivatsan K C
PUBLISHED ON JAN 04, 2021 06:51 PM IST
DGCI said that the second dose should be administered between four to six weeks after the first dose and also noted that there is data available for administration of the second dose up to 12 weeks after the first dose from the overseas studies.
A health worker takes part in a dry run or a mock drill for Covid-19 coronavirus vaccine delivery at a model vaccination centre at Ansari Road in New Delhi on Saturday.(Sanchit Khanna/HT Photo)
A health worker takes part in a dry run or a mock drill for Covid-19 coronavirus vaccine delivery at a model vaccination centre at Ansari Road in New Delhi on Saturday.(Sanchit Khanna/HT Photo)

After Covishield and Covaxin, these are other Covid-19 vaccine candidates in India

Hindustan Times, New Delhi | By hindustantimes.com | Edited by Meenakshi Ray
UPDATED ON JAN 04, 2021 09:09 AM IST
Drugs Controller General of India VG Somani gave the green light for the emergency-use of two coronavirus vaccines, one developed by AstraZeneca and Oxford University and the other by local company Bharat Biotech.
Drugs Controller General of India (DCGI) Dr V G Somani addresses a press conference to announce the approval of Oxford Covid-19 vaccine Covishield, manufactured by the Serum Institute, and indigenously developed Covaxin of Bharat Biotech for restricted emergency use in the country, in New Delhi.(PTI)
Drugs Controller General of India (DCGI) Dr V G Somani addresses a press conference to announce the approval of Oxford Covid-19 vaccine Covishield, manufactured by the Serum Institute, and indigenously developed Covaxin of Bharat Biotech for restricted emergency use in the country, in New Delhi.(PTI)

Cong, BJP trade barbs over Indian vaccine’s DCGI nod

Hindustan Times, New Delhi | By HTC and Agencies
PUBLISHED ON JAN 04, 2021 03:59 AM IST
India’s drugs regulator DCGI on Sunday approved Oxford’s Covid-19 vaccine, Covishield, and Bharat Biotech’s Covaxin for restricted emergency use.
A conspiracy theory claimed that Bill Gates had planned to use a potential Covid-19 vaccine to implant microchips to monitor the movement of billions of people.(AP)
A conspiracy theory claimed that Bill Gates had planned to use a potential Covid-19 vaccine to implant microchips to monitor the movement of billions of people.(AP)

From ‘impotency’ to ‘microchip’: Dangerous conspiracy theories surrounding Covid-19, vaccines

Hindustan Times, New Delhi | By hindustantimes.com | Edited by Kunal Gaurav
UPDATED ON JAN 04, 2021 05:37 PM IST
While the governments and health authorities have been working to contain the virus and slow down its transmission, they have also been struggling to put a lid on wild and baseless conspiracy theories.
The DCGI granted the approval on the basis of recommendations of a Covid-19 Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO).(PTI)
The DCGI granted the approval on the basis of recommendations of a Covid-19 Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO).(PTI)

DCGI gives licensing permission to Bharat Biotech to manufacture Covaxin

Hindustan Times, New Delhi | By hindustantimes.com| Edited by Susmita Pakrasi
UPDATED ON JAN 03, 2021 08:58 PM IST
The DCGI gave final approval to two Covid-19 vaccines, paving the way for a huge inoculation program to stem the pandemic in the second worst-hit country.
Health workers and candidate during Covid-19 vaccine dry run at District Hospital, Aundh, in Pune.(Pratham Gokhale/HT Photo)
Health workers and candidate during Covid-19 vaccine dry run at District Hospital, Aundh, in Pune.(Pratham Gokhale/HT Photo)

Congress leaders raise concern over DCGI approval to indigenous Covid-19 vaccine

New Delhi | By Press Trust of India | Posted by Shivani Kumar
UPDATED ON JAN 03, 2021 05:42 PM IST
However, there were different voices within the party as its chief spokesperson Randeep Surjewala lauded scientists and researchers of Bharat Biotech for the indigenous vaccine.
A medic fills a syringe with Covaxin, a government-backed experimental Covid-19 vaccine, before administering it to a health worker during its trials.(Reuters File Photo)
A medic fills a syringe with Covaxin, a government-backed experimental Covid-19 vaccine, before administering it to a health worker during its trials.(Reuters File Photo)

Approval for Covaxin a giant leap for novel product development in India: Bharat Biotech

New Delhi | By Press Trust of India | Posted by Kanishka Sarkar
PUBLISHED ON JAN 03, 2021 02:58 PM IST
The phase-III human clinical trials of Covaxin began mid-November. Bharat Biotech aims to recruit 26,000 volunteers across the country for the phase-III trials.
Drugs Controller General of India (DCGI) Dr V G Somani during a press conference to announce the approval of Oxford COVID-19 vaccine Covishield, manufactured by the Serum Institute, and indigenously developed Covaxin of Bharat Biotech for restricted emergency use in the country, in New Delhi.(PTI)
Drugs Controller General of India (DCGI) Dr V G Somani during a press conference to announce the approval of Oxford COVID-19 vaccine Covishield, manufactured by the Serum Institute, and indigenously developed Covaxin of Bharat Biotech for restricted emergency use in the country, in New Delhi.(PTI)

Vaccines 100% safe, rumours of impotency is ‘absolute rubbish’: Somani

Hindustan Times, New Delhi | By hindustantimes.com | Edited by Shankhyaneel Sarkar
UPDATED ON JAN 03, 2021 01:47 PM IST
Somani was trying to dispel rumours associated with vaccines as anti-vaccination groups continued to challenge the need and safety of the shots not only in India but also in several other countries despite rising Covid-19 cases and deaths.
Representational image.(REUTERS)
Representational image.(REUTERS)

India likely to start the new year with a Covid vaccine, hints DCGI

Hindustan Times, New Delhi | By Anonna Dutt
UPDATED ON DEC 31, 2020 02:42 PM IST
The Subject Expert Committee will meet on January 1 to consider the emergency-use authorisation application of Pfizer, Serum Institute of India, and Bharat Biotech’s Covaxin
The man has served a legal notice on Pune-based SII, claiming to have suffered a virtual neurological breakdown and impairment of cognitive functions, seeking Rs 5 crore in compensation and a halt to the trial.(REUTERS)
The man has served a legal notice on Pune-based SII, claiming to have suffered a virtual neurological breakdown and impairment of cognitive functions, seeking Rs 5 crore in compensation and a halt to the trial.(REUTERS)

SII to sue man over claims of Covishield side effects

Hindustan Times, Chennai/New Delhi | By HT Correspondent and PTI, Chennai/new Delhi
PUBLISHED ON NOV 30, 2020 02:29 AM IST
When contacted, a spokesperson for Sri Ramachandra Institute of Higher Education and Research said the institute had received the notice, but declined to elaborate.
FILE PHOTO: AstraZeneca's logo is reflected in a drop on a syringe needle in this illustration taken November 9, 2020. REUTERS/Dado Ruvic/Illustration(REUTERS)
FILE PHOTO: AstraZeneca's logo is reflected in a drop on a syringe needle in this illustration taken November 9, 2020. REUTERS/Dado Ruvic/Illustration(REUTERS)

Biocon chief hopes for DCGI nod for Oxford-AstraZeneca Covid-19 vaccine in emergency cases

New Delhi | By Press Trust of India | Posted by Karan Manral
UPDATED ON NOV 24, 2020 02:18 PM IST
Referring to “100 Million Doses By January” remark by Serum Institute of India CEO Adar Poonawalla, Kiran Mazumdar-Shaw tweeted that she hopes that the Drugs Controller General of India (DCGI) will give its nod as soon as it gets approval from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA).
At present, there are eight vulture conservation breeding centres across the country.(HT archive)
At present, there are eight vulture conservation breeding centres across the country.(HT archive)

Centre to regulate sale of veterinary NSAIDS to boost vulture numbers

Hindustan Times, New Delhi | By Jayashree Nandi
UPDATED ON NOV 16, 2020 05:00 PM IST
Regulating the sale of veterinary NSAIDs can prevent poisoning of cattle carcasses, which is the primary source of sustenance for vultures
Dr Reddy’s Laboratories’ had applied to DCGI seeking permission for full marketing authorisation of remdesivir injection after US Food and Drug Administration (FDA) cleared it for treating hospitalised Covid-19 patients.(AP file photo)
Dr Reddy’s Laboratories’ had applied to DCGI seeking permission for full marketing authorisation of remdesivir injection after US Food and Drug Administration (FDA) cleared it for treating hospitalised Covid-19 patients.(AP file photo)

DCGI rejects Dr Reddy’s Laboratories’ application for full marketing authorisation of remdesivir

New Delhi | By Press Trust of India | Posted by Deepali Sharma
PUBLISHED ON NOV 02, 2020 10:11 PM IST
The Union health ministry in its ‘Clinical Management Protocols for Covid-19’ has recommended the use of remdesivir in Covid-19 patients in the moderate stages of the illness.
Three out of four bills passed by the Congress-led Punjab government on October 20 to negate contentious central legislations on how farmers do business are unlikely to invalidate the laws already passed by Parliament(AP)
Three out of four bills passed by the Congress-led Punjab government on October 20 to negate contentious central legislations on how farmers do business are unlikely to invalidate the laws already passed by Parliament(AP)

News updates from Hindustan Times:Punjab farm bills offer little on ground and all the latest news

Hindustan Times, New Delhi | By hindustantimes.com
UPDATED ON OCT 24, 2020 09:18 AM IST
:A healthcare worker is seen during swab test of the people in Chembur in Mumbai.(Pratik Chorge/HT Photo)
:A healthcare worker is seen during swab test of the people in Chembur in Mumbai.(Pratik Chorge/HT Photo)

Bharat Biotech’s Covid-19 vaccine gets nod for Phase 3 trial. Here’s how it came through

Hindustan Times, New Delhi | By hindustantimes.com | Edited by Meenakshi Ray
UPDATED ON OCT 23, 2020 10:02 PM IST
A subject expert committee on Covid-19 had recommended granting permission to Bharat Biotech for conducting latest phase of the clinical trial of its vaccine ‘Covaxin’ after assessing the safety and immunogenicity data of Phase 1 and Phase 2 trials.
The panel added that the recommendation is after assessing data from Phase I & II as well as animal challenge study.(HT file photo)
The panel added that the recommendation is after assessing data from Phase I & II as well as animal challenge study.(HT file photo)

Covaxin: Bharat Biotech gets nod from DCGI panel for Phase III trials

Livemint, New Delhi | By Mint Correspondent
UPDATED ON OCT 23, 2020 08:32 AM IST
The nod is subject to amendment in how primary efficacy endpoint for symptomatic cases be studied in Phase 3 trials, the panel further stated.
Bharat Biotech, indigenously developed vaccine candidate by Zydus Cadila Ltd is in the phase 2 of the human clinical trials.
Bharat Biotech, indigenously developed vaccine candidate by Zydus Cadila Ltd is in the phase 2 of the human clinical trials.

Bharat Biotech asked to submit complete phase 2 data of its Covid-19 vaccine

New Delhi | By Press Trust of India | Posted by Kanishka Sarkar
UPDATED ON OCT 10, 2020 06:54 PM IST
The vaccine candidate -- ‘Covaxin’ -- is being indigenously developed by the Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR).
The FAITH study enrolled a total of 158 hospitalised patients with moderate symptoms of Covid-19 in India.(REUTERS File)
The FAITH study enrolled a total of 158 hospitalised patients with moderate symptoms of Covid-19 in India.(REUTERS File)

Combination of antiviral drugs shows ‘no superior outcome’ for Covid treatment: Firm

Hindustan Times, New Delhi | By Rhythma Kaul
PUBLISHED ON OCT 10, 2020 10:04 AM IST
In May, Glenmark had received approval from DCGI to conduct phase 3 clinical trials in the country using a combination of antiviral drugs Favipiravir and Umifenovir as a potential Covid-19 treatment strategy
The experimental AZD1222 is regarded as the front runner for a Covid-19 vaccine and is the only candidate in phase 2/3 trials among Indians.(Reuters image)
The experimental AZD1222 is regarded as the front runner for a Covid-19 vaccine and is the only candidate in phase 2/3 trials among Indians.(Reuters image)

SII told to seek fresh clearance for Covid-19 vaccine trials

Hindustan Times, New Delhi/London | By Rhythma Kaul and Prasun Sonwalkar, New Delhi/london
UPDATED ON SEP 13, 2020 01:24 AM IST
DCGI has also directed the Pune-based vaccine producer to closely follow up on all the individuals who have been administered vaccine doses as part of the trial so far and submit a report immediately.
On August 2, the DCGI had granted permission to the Pune-based SII to conduct Phase 2 and 3 human clinical trials of the coronavirus vaccine candidate.(REUTERS)
On August 2, the DCGI had granted permission to the Pune-based SII to conduct Phase 2 and 3 human clinical trials of the coronavirus vaccine candidate.(REUTERS)

Serum Institute ordered to suspend recruitment for Covid-19 vaccine trials: Report

New Delhi | By Press Trust of India| Posted by Susmita Pakrasi
PUBLISHED ON SEP 12, 2020 07:42 AM IST
Earlier this week, AstraZeneca said it had paused the trials because of ‘an unexplained illness’ in a participant in the study. 
Covaxin trials are being conducted on 1,125 patients at 12 hospitals across the country
Covaxin trials are being conducted on 1,125 patients at 12 hospitals across the country

Covaxin gets nod for skin trial: Latest on India’s Covid-19 vaccine candidate

Hindustan Times, New Delhi | By hindustantimes.com | Edited by Kanishka Sarkar
UPDATED ON AUG 23, 2020 09:19 AM IST
Human trials of Covaxin started about two week ago and it may be available by the end of the year, Union minister of health and family welfare Harsh Vardhan has said.
SHARE
  • 1
  • 2
  • ...
Story Saved